Charles River Laboratories International, Inc. (CRL) Stake Lessened by SG Americas Securities LLC

SG Americas Securities LLC cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 67.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,692 shares of the medical research company’s stock after selling 13,984 shares during the period. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $723,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in CRL. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 0.5% during the second quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock valued at $511,893,000 after purchasing an additional 27,217 shares during the period. BlackRock Inc. grew its holdings in Charles River Laboratories International by 4.6% during the second quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock valued at $406,913,000 after purchasing an additional 177,239 shares during the period. FMR LLC grew its holdings in Charles River Laboratories International by 23.8% during the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock valued at $311,458,000 after purchasing an additional 591,066 shares during the period. State Street Corp grew its holdings in Charles River Laboratories International by 2.3% during the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock valued at $128,288,000 after purchasing an additional 28,365 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Charles River Laboratories International by 14.4% during the second quarter. Renaissance Technologies LLC now owns 1,219,883 shares of the medical research company’s stock valued at $123,391,000 after purchasing an additional 153,374 shares during the period. 96.27% of the stock is owned by institutional investors.

Shares of Charles River Laboratories International, Inc. (CRL) opened at $102.48 on Thursday. The stock has a market capitalization of $4,822.35, a price-to-earnings ratio of 20.00, a price-to-earnings-growth ratio of 1.62 and a beta of 0.89. Charles River Laboratories International, Inc. has a 12-month low of $72.06 and a 12-month high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.08. The firm had revenue of $464.23 million for the quarter, compared to the consensus estimate of $458.93 million. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.18 earnings per share. sell-side analysts forecast that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The disclosure for this sale can be found here. In the last 90 days, insiders have acquired 10,500 shares of company stock worth $2,885. Company insiders own 2.20% of the company’s stock.

Several brokerages have weighed in on CRL. Robert W. Baird set a $117.00 price objective on Charles River Laboratories International and gave the company a “buy” rating in a report on Monday, November 13th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price objective for the company in a report on Thursday, August 10th. Bank of America reduced their price objective on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th. Jefferies Group increased their price objective on Charles River Laboratories International from $120.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 9th. Finally, Royal Bank Of Canada started coverage on Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price on the stock. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $106.63.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Stake Lessened by SG Americas Securities LLC” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/07/charles-river-laboratories-international-inc-crl-stake-lessened-by-sg-americas-securities-llc.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply